dr. reddy's laboratories
Uday Saxena Ph.D.
Former Chief Scientific Officer, Member of the Scientific Advisory Board, Chief Executive Officer of Reddy US Therapeutics Inc and President of Reddy US Therapeutics Inc, Dr. Reddy's Laboratories Ltd.
|Age||Total Calculated Compensation||This person is connected to 11 board members in 2 different organizations across 2 different industries.|
See Board Relationships
Dr. Uday Saxena, Ph.D., is the Co-Founder and Chief Advisor R&D at Kareus Therapeutics, SA and serves as a Member of Strategic Advisory Team. Dr. Saxena served as the President and Chief Executive Officer of Reddy US Therapeutics, Inc., since 2002 and Chief Scientific Officer of Dr. Reddy's Laboratories Ltd. He oversaw global R&D at Dr. Reddy's. He served as member of the management council for Dr. Reddy's Laboratories Ltd. He served as Vice President of Research and ...
8-2-337, Road No. 3Phone: 91 40 4900 2900
Hyderabad, Andhra Pradesh 500034
Fax: 91 40 4900 2999
Board Members Memberships*There is no Board Members Memberships data available.
Memorial University Of Newfoundland
University of Hyderabad
Annual Compensation*There is no Annual Compensation data available.
Stock Options*There is no Stock Options data available.
Total Compensation*There is no Total Compensation data available.
|Rajiv Kanishka Liyanaarchchie De Silva||Chief Executive Officer, President and Director|
Endo International plc
|Stephen Edward Foots||Chief Executive Officer, Executive Director, Chairman of Group Executive Committee, Member of Risk Management Committee, Member of Routine Business Committee, Member of Nomination Committee, Member of Finance Committee and Member of Group Safety, Health & Environment Steering Committee|
Croda International plc
|Heinz-Jürgen Bertram Ph.D.||Chairman of Executive Board, Chief Executive Officer and Labour Director|
|Subhanu Saxena||Managing Director, Global Chief Executive Officer and Director|
|Narayanan Govindarajan||Managing Director and Director|
Aurobindo Pharma Limited
|15.9M||Compensation as of Fiscal Year 2013.|